Drug Development

Clinical Trials Clinical Research Therapeutics Oncology Cancer Research Regulatory Affairs Cancer Treatments Formulation Science Research and Development Targeted Therapies

3 ARTICLES

last mo.

Takeda Signs $600 Million‑Value AI Drug Discovery Deal With Insilico

The agreement signals Takeda's move toward an AI‑native discovery model by channeling Insilico's generative Pharma.AI into its clinical development pipeline.

4 ARTICLES

3mo ago

Trump Order to Speed Psychedelic Therapies Sends Compass Pathways to 52-Week High

9 ARTICLES

4mo ago

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

3 ARTICLES

4mo ago

Traws Pharma Raises $10 Million in PIPE With Up to $60 Million Tied to Trial Milestones

5 ARTICLES

4mo ago

Dog Longevity Pill Advances After FDA Safety Check

4 ARTICLES

5mo ago

RTW Buys $116 Million of Cogent Biosciences as Kynam Trims $48 Million Stake

3 ARTICLES

5mo ago

Scientists Report New Trisulfide Metathesis Reaction That Rewrites S–S–S Bond Chemistry

4 ARTICLES

5mo ago

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

7 ARTICLES

6mo ago

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

13 ARTICLES

6mo ago

AstraZeneca Pledges $15 Billion China Expansion Through 2030

6 ARTICLES

7mo ago

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

4 ARTICLES

7mo ago

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

3 ARTICLES

7mo ago

Insilico and Servier Strike Up to $888 Million AI-Oncology Partnership

4 ARTICLES

8mo ago

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

Drug Development

Takeda Signs $600 Million‑Value AI Drug Discovery Deal With Insilico

Akari’s AKTX-101 Shows Preclinical Synergy With KRAS Inhibitor as Stock Soars

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Altimmune Targets Second-Half 2026 Launch for Global Phase 3 MASH Trial

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

Erasca Shares Plunge After Trial Death and Patent Challenge

Sagimet Prices $175 Million Stock Offering as It Plans U.S. Phase 3 Acne Trial

Trump Order to Speed Psychedelic Therapies Sends Compass Pathways to 52-Week High

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

Traws Pharma Raises $10 Million in PIPE With Up to $60 Million Tied to Trial Milestones

Never miss stories about

Drug Development

Dog Longevity Pill Advances After FDA Safety Check

RTW Buys $116 Million of Cogent Biosciences as Kynam Trims $48 Million Stake

Scientists Report New Trisulfide Metathesis Reaction That Rewrites S–S–S Bond Chemistry

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

AstraZeneca Pledges $15 Billion China Expansion Through 2030

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Insilico and Servier Strike Up to $888 Million AI-Oncology Partnership

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

Never miss stories about

Drug Development